Fitch changes Allergan view

Fitch Ratings said it affirmed the ratings of Allergan plc and its subsidiaries at BBB- and revised the outlook to positive from stable.

The agency said the outlook is supported by the company's strengthening credit metrics and Fitch's expectation that Allergan will operate with total debt/EBITDA at or below 3x beginning in 2020 under a forecast that includes generic competition for Restasis entering the market in 2019.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.